Hsu, P.-C.; Huang, C.-Y.; Wang, C.-C.; Kuo, S.C.-H.; Chu, C.-H.; Tung, P.-H.; Huang, A.C.-C.; Wang, C.-L.; Chiu, L.-C.; Fang, Y.-F.;
et al. The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study. Pharmaceuticals 2020, 13, 331.
https://doi.org/10.3390/ph13110331
AMA Style
Hsu P-C, Huang C-Y, Wang C-C, Kuo SC-H, Chu C-H, Tung P-H, Huang AC-C, Wang C-L, Chiu L-C, Fang Y-F,
et al. The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study. Pharmaceuticals. 2020; 13(11):331.
https://doi.org/10.3390/ph13110331
Chicago/Turabian Style
Hsu, Ping-Chih, Chun-Yao Huang, Chin-Chou Wang, Scott Chih-Hsi Kuo, Chia-Hsun Chu, Pi-Hung Tung, Allen Chung-Cheng Huang, Chih-Liang Wang, Li-Chung Chiu, Yueh-Fu Fang,
and et al. 2020. "The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study" Pharmaceuticals 13, no. 11: 331.
https://doi.org/10.3390/ph13110331
APA Style
Hsu, P.-C., Huang, C.-Y., Wang, C.-C., Kuo, S. C.-H., Chu, C.-H., Tung, P.-H., Huang, A. C.-C., Wang, C.-L., Chiu, L.-C., Fang, Y.-F., & Yang, C.-T.
(2020). The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study. Pharmaceuticals, 13(11), 331.
https://doi.org/10.3390/ph13110331
